Abu Dhabi, UAE, April 29, 2019.
UAE based global pharmaceutical manufacturer, Neopharma, announced that it has entered into a definitive agreement with GlaxoSmithKline (GSK), a global science-led pharmaceutical company, to enable commercialization of six critical products for GSK. The partnership is another milestone to signify a strategic collaboration with globally renowned MNCs.
This partnership will enable steadier and seamless supply of critical GSK’s products, respond to address supply gaps in a quick and efficient manner and will positively help patients by ensuring access to critical products.
The ceremony, held at the British Embassy in Abu Dhabi, was officiated by His Excellency Patrick Moody, the British Ambassador to the United Arab Emirates, Dr B.R. Shetty, Founder and Chairman of Neopharma and Sameh Elfangary, General Manager at GSK in the Gulf. In attendance were also high-ranking officials and representatives including His Excellency Khalfan Al Suwaidi, Industrial Property Director at Ministry of Economy, and Her Excellency Dr Ola Ghaleb Al Ahdab, Pharmaceutical Advisor at Drug Department, Ministry of Health and Prevention
The UK Ambassador to the UAE, His Excellency Mr. Patrick Moody said “I am very proud to see the commitment of one of our most important UK innovator Pharma companies to the UAE vision. This will solidify important partnerships working with the UAE Ministry of Health and Prevention”. He added “This links the strategies and development visions of both countries, especially the objectives of the UAE Vision 2021, which aims to strengthen the status of the country as a major commercial and logistical hub in the region, and the UK’s Industrial Strategy and Export Strategy, which aims to strengthen the UK's position as a global exporter”.
Dr. B.R. Shetty, Founder & Chairman, Neopharma said “It is a landmark to have a collaboration with another leading innovator company GSK as a partner. We have become partner of choice for MNCs over a period. This is further affirmation of Neopharma’s commitment to maintain global quality and manufacturing standards which are compliant to stringent regulatory requirements. This partnership reinforces UAE’s vision to become a pharmaceutical manufacturing hub in the region.”
Suresh Kumar Nandiraju, Chief Operating Officer, Neopharma, said, “This collaboration with GSK will ensure the access of quality medicines in UAE. It affirms that Neopharma is committed to adhere to global quality and best manufacturing practices.”
Sameh Elfangary, General Manager at GSK in the Gulf, said: “At GSK, we are committed to ensuring the quality, safety and reliable supply of our products. The collaboration will be fully operational by early 2020 in the UAE and will cover medications that are in high demand locally. This operation will help ensure continuity in supply and improved patient access to GSK medicines in the market. We are grateful to have partnered with a trusted pharmaceutical company with a large global footprint, such as Neopharma, and are already exploring possibilities for expansion plans within the next two years.”
Neopharma, is one of the largest pharmaceutical companies in the MENA region with 100% subsidiaries in USA, Japan, Brazil, and India. A vertically integrated business, comprising of API, R&D and Formulation facilities in emerging and regulated markets. This enable us to deliver quality innovative and generic products in a timely manner at affordable prices in over 50 countries worldwide. Neopharma's global presence is supported by 7 manufacturing facilities spread across 4 continents delivering a wide range of branded and generic formulations, and active pharmaceutical ingredients (APIs). The therapeutic segments covered are acute and chronic therapies. For further information, log on to: www.neopharma.com
GSK is science-led global healthcare company with a special purpose to help people do more, feel better, live longer. Globally and regionally, we have a proven track-record for providing high quality medicines, vaccines and consumer products. GSK has a 300-year global legacy and more than 70 years of local presence in the Gulf region. Today, GSK is one of the most innovative and best performing companies in the region, providing medical well-being to millions of people in the region.